Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.

The human androgen receptor (AR) is a proven therapeutic target in prostate cancer. All current antiandrogens, such as Bicalutamide, Flutamide, Nilutamide, and Enzalutamide, target the buried hydrophobic androgen binding pocket of this protein. However, effective resistance mechanisms against these therapeutics exist such as mutations occurring at the target site. To overcome these limitations, the surface pocket of the AR called binding function 3 (BF3) was characterized as an alternative target for small molecule therapeutics. A number of AR inhibitors directly targeting the BF3 were previously identified by us ( J. Med. Chem. 2011 . 54 , 8563 ). In the current study, based on the prior results, we have developed structure-activity relationships that allowed designing a series of 2-((2-phenoxyethyl)thio)-1H-benzimidazole and 2-((2-phenoxyethyl)thio)-1H-indole as lead BF3 inhibitors. Some of the developed BF3 ligands demonstrated significant antiandrogen potency against LNCaP and Enzalutamide-resistant prostate cancer cell lines.

[1]  C S Song,et al.  Regulation of androgen action. , 1999, Vitamins and hormones.

[2]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[3]  A. Parent,et al.  Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. , 2009, ACS chemical biology.

[4]  S. Arya,et al.  The LNCaP cell line--a new model for studies on human prostatic carcinoma. , 1980, Progress in clinical and biological research.

[5]  R. Fletterick,et al.  Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells , 2011, Proceedings of the National Academy of Sciences.

[6]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[7]  J. Dalton,et al.  Chemistry and Structural Biology of Androgen Receptor , 2005 .

[8]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[9]  L. Mayr,et al.  Evaluation of two novel tag-based labelling technologies for site-specific modification of proteins. , 2006, International journal of biological macromolecules.

[10]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[11]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[12]  H. Scher,et al.  Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.

[13]  N. Dawson,et al.  Emerging therapies in castrate-resistant prostate cancer , 2009, Current opinion in oncology.

[14]  P. Carroll,et al.  20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .

[15]  Peyman Tavassoli,et al.  Rapid, non‐destructive, cell‐based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells , 2007, The Prostate.

[16]  Michelle R. Arkin,et al.  Binding of small molecules to an adaptive protein–protein interface , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Gleave,et al.  Intermittent androgen suppression for prostate cancer: rationale and clinical experience , 1998, Prostate Cancer and Prostatic Diseases.

[18]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[19]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[20]  Artem Cherkasov,et al.  Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening. , 2011, Journal of medicinal chemistry.

[21]  G. Bubley,et al.  Biology of prostate-specific antigen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Solène Grosdidier,et al.  Allosteric conversation in the androgen receptor ligand-binding domain surfaces. , 2012, Molecular endocrinology.

[23]  Phuong Nguyen,et al.  A surface on the androgen receptor that allosterically regulates coactivator binding , 2007, Proceedings of the National Academy of Sciences.

[24]  H. Scher,et al.  ARN-509: a novel antiandrogen for prostate cancer treatment. , 2012, Cancer research.

[25]  Artem Cherkasov,et al.  Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. , 2011, Journal of medicinal chemistry.

[26]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[27]  P. Kantoff,et al.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[29]  D. Horsfall,et al.  Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. , 1994, Cancer research.

[30]  R. Guy,et al.  Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. , 2009, ACS chemical biology.

[31]  I. Tannock,et al.  Drug resistance in metastatic castration-resistant prostate cancer , 2011, Nature Reviews Clinical Oncology.

[32]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[33]  Mary J. Meegan,et al.  “True” Antiandrogens—Selective Non-Ligand-Binding Pocket Disruptors of Androgen Receptor–Coactivator Interactions: Novel Tools for Prostate Cancer , 2012, Journal of medicinal chemistry.

[34]  B. Furr,et al.  The development of Casodex (bicalutamide): preclinical studies. , 1996, European urology.